{"id":"W2150308444","doi":"10.1007/s10637-010-9444-0","title":"A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Académie française","keywords":"Nimotuzumab; Medicine; Toxicity; Epidermal growth factor receptor; Pharmacodynamics; Rash; Pharmacology; Internal medicine; Cetuximab; Pharmacokinetics; Phases of clinical research; Oncology; Monoclonal antibody; Antibody; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001317556,0.001406212,0.001879831,0.0004840121,0.0004294393,0.0009396631,0.0008354723,0.001095732,0.003076541],"category_scores_gemma":[0.001108903,0.0003973426,0.001071376,0.0004602381,0.0009372548,0.001099251,0.0004869621,0.003610696,0.0007452776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068157,"about_ca_system_score_gemma":0.001146502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001024451,"about_ca_topic_score_gemma":0.003189988,"domain_scores_codex":[0.999632,0.000168831,0.00001456418,0.0000640795,0.0000314702,0.00008902134],"domain_scores_gemma":[0.9993998,0.0001109458,0.0000682813,0.00005693354,0.00002535138,0.000338717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6766587,0.06611189,0.008279435,0.0006566126,0.001516717,0.0004649655,0.000693174,0.00736522,0.0334137,0.001160058,0.01227135,0.1914081],"study_design_scores_gemma":[0.7646734,0.2065655,0.01495508,0.00003254411,0.0003624628,0.0004398037,0.00009342579,0.003267334,0.002982003,0.0008807951,0.00570884,0.00003890587],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909728,0.001492636,0.0006268179,0.001224115,0.0002212932,0.001423629,0.0009527787,0.0001140905,0.002971947],"genre_scores_gemma":[0.9863121,0.001360706,0.002510788,0.001536782,0.0001666777,0.001514855,0.002764375,0.00005197146,0.003781755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003076541,"threshold_uncertainty_score":0.01029211,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02755508365146138,"score_gpt":0.3533887031160662,"score_spread":0.3258336194646049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}